Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lannett has signed an agreement to acquire abbreviated new drug applications (ANDAs) for two generic pharmaceutical products.
Subscribe to our email newsletter
Under the agreement, the company has purchased ANDAs for 0.5mg, 1mg and 2mg Estradiol Tablets, and 5mg Selegiline Hydrochloride Capsules.
The seller’s identity and the financial terms of the transaction remain undisclosed.
Lannett president and chief executive officer Arthur Bedrosian said: "The acquisition of these two important medications further expands and diversifies our product portfolio and complements our internal research and development efforts."
The company plans to launch Estradiol Tablets within the next several months, and Selegiline Hydrochloride Capsules sometime thereafter.
In 2013, the total sales of 0.5mg, 1mg and 2mg Estradiol Tablets, and 5mg Selegiline Hydrochloride Capsules at average wholesale price (AWP) were $31m and $8.5m, respectively, according to IMS.
The reference listed drug manufacturer for Estradiol Tablets is Barr Laboratories, while 5mg Selegiline Hydrochloride Capsules is the generic equivalent of Somerset Pharmaceuticals’ Eldepryl.